본문 바로가기

HOME
Science

한미약품의 혁신적인 R&D 파이프라인을 한눈에 볼 수 있습니다.

한미약품의 혁신적인 R&D 파이프라인.

라이센싱 파트너십 문의

에포시페그트루타이드 (LAPSTriple agonist)

비만 / 대사

임상2상

개요
최적화된 삼중 작용을 통한 다중 표적 관여
"MASH/섬유증에 적합한 인크레틴“
에포시페그트루타이드는 글루카곤, 위 억제 펩타이드(GIP) 및 글루카곤 유사 펩타이드-1(GLP-1) 활성을 지니는 약제가 인간 면역글로불린의 불변부위와 화학적으로 결합되어 있는 지속형 3중 작용제입니다.

글루카곤, GIP 및 GLP-1 수용체에 대한 동시적이고 최적화된 작용은 지방간, 염증 및 섬유화 개선 모두에 긍정적인 영향을 미침으로써 단일 표적 약물 대비, 대사이상관련간염 (비알코올성지방간염) 및 섬유증 환자에 향상된 치료 효능을 제공할 수 있습니다.

다양한 MASH 및 간 섬유증 동물 모델을 활용한 비임상 연구에서 에포시페그트루타이드는 지방간을 개선할 뿐만 아니라, 간 염증 및 섬유증에도 우수한 치료 효능이 있다는 것이 확인되었습니다. 이러한 결과를 바탕으로 FDA는 에포시페그트루타이드를 MASH 치료를 위한 신속 심사 대상으로 지정했습니다. 현재 에포시페그트루타이드는 생검을 통해 MASH 가 확인된 환자를 대상으로 약물의 효능과 유효성 평가하는 임상 2b상을 진행 중입니다. 뿐만 아니라, 미충족 의료 수요가 높은 다양한 섬유성 질환에 대한 에포시페그트루타이드의 적응증 확대 연구 또한 활발하게 수행하고 있습니다. 이를 바탕으로 에포시페그트루타이드는 특발성 폐섬유증(IPF), 원발성 담즙성 담관염(PBC), 원발성 경화성 담관염(PSC) 치료를 위한 FDA 및 EMA 희귀의약품으로도 지정 됐습니다.
설명
글루카곤/GIP/GLP-1 삼중 작용
  • 다중 인크레틴 작용을 통한 지방간 개선 효능 극대화
  • 간 표적 및 다중 인크레틴 작용을 통한 간 염증 개선 효능 극대화
  • 직접적인 간 성상세포 활성화 및 섬유화 억제
지속형 플랫폼인 랩스커버리가 적용된, 주 1회 투여가 가능한 first-in class 3중 작용제
이미지 확대 보기
임상 개발
공개 자료
포스터
Glucagon engagement is essential for the direct anti-inflammation and anti-fibrosis effect of efocipegtrutide in TAA-induced mouse model of liver injury and fibrosis​
American Association for the Study of Liver Disease (AASLD) Meeting, 2024
Download
포스터
Improvement of liver fibrosis by a novel long acting glucagon/GIP/GLP-1 triple agonist, efocipegtrutide (HM15211) in carbon tetrachloride-induced mouse model of liver injury and fibrosis
European Association for the Study of the Liver (EASL) Congress, 2023
Download
포스터
Anti-inflammatory and anti-fibrotic effects by simultaneous activation of glucagon, GIP, and GLP-1 of efocipegtrutide (HM15211) in thioacetamide-induced mouse model of liver injury and fibrosis
European Association for the Study of the Liver (EASL) Congress, 2023
Download
포스터
Anti-fibrotic and mortality reduction potential of a novel long-acting glucagon/GIP/GLP-1 triple agonist (HM15211) in preclinical models of idiopathic pulmonary fibrosis
American Thoracic Society (ATS) International conference, 2023
Download
발표
Anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in TAA induced mouse model of liver injury and fibrosis
European association for the study of diabetes (EASD) 58th Annual meeting, 2022
Download
발표
Anti-fibrotic potential of a novel long-acting Glucagon/GIP/GLP-1 triple agonist (HM15211) in preclinical models of idiopathic pulmonary fibrosis
European association for the study of diabetes (EASD) 58th Annual meeting, 2022
Download
포스터
Direct Anti-inflammatory and Anti-fibrotic Effects of a Novel Long-acting Glucagon/GIP/GLP-1 Triple Agonist, HM15211, in TAA-induced Mouse Model of Liver Injuary and Fibrosis
American diabetes association (ADA) 82nd Scientific sessions, 2022
Download
포스터
Anti-fibrotic potential of a novel long-acting Glucagon/GIP/GLP-1 triple agonist (HM15211) in preclinical models of fibrosis
American diabetes association (ADA) 81st Scientific sessions, 2021
Download
발표
Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist (HM15211) in animal model of NASH
European association for the study of diabetes (EASD) 57th Annual meeting, 2021
Download
포스터
Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211)in CDHFD-induced NASH and fibrosis mice
American diabetes association (ADA) 80th Scientific sessions, 2020
Download
포스터
HM15211, a novel long-acting GLP-1/GIP/Glucagon triple agonist, exhibits anti-inflammatory and –fibrotic effects in AMLN/TAA induced liver inflammation and fibrosis mice
American diabetes association (ADA) 80th Scientific sessions, 2020
Download
포스터
Anti-fibrotic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in BDL-induced liver fibrosis mice
American diabetes association (ADA) 80th Scientific sessions, 2020
Download
포스터
Effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in a NASH and liver fibrosis animal models
European association for the study of diabetes (EASD) 55th Annual meeting, 2019
Download
포스터
Effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in a dyslipidemia animal models
European association for the study of diabetes (EASD) 55th Annual meeting, 2019
Download
포스터
Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/Glucagon triple agonist in the neurodegenerative disease models
European association for the study of diabetes (EASD) 55th Annual meeting, 2019
Download
포스터
A double-blinded, placebo controlled, single ascending dose study for safety, tolerability, pharmacokinetics, and pharmacodynamics after subcutaneous administration of novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in healthy obese subjects
American diabetes association (ADA) 79th Scientific sessions, 2019
Download
포스터
Effect of HM15211, a novel long-Acting GLP-1/GIP/Glucagon triple agonist in the neurodegenerative disease models
American diabetes association (ADA) 79th Scientific sessions, 2019
Download
포스터
Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in a dyslipidemia animal model
American diabetes association (ADA) 79th Scientific sessions, 2019
Download
포스터
Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in a NASH and fibrosis animal model
American diabetes association (ADA) 79th Scientific sessions, 2019
Download
포스터
Novel combination of GLP-1/GIP/Glucagon triple agonist (HM15211) and once-weekly basal insulin offers improved glucose lowering and weight loss in a diabetic animal model
European association for the study of diabetes (EASD) 54th Annual meeting, 2018
Download
포스터
Bone protective effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in the obese-osteoporosis rodent model
European association for the study of diabetes (EASD) 54th Annual meeting, 2018
Download
발표
Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/Glucagon triple agonist in the neurodegenerative disease models
European association for the study of diabetes (EASD) 54th Annual meeting, 2018
Download
발표
Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in NASH and fibrosis animal models
American diabetes association (ADA) 78th Scientific sessions, 2018
Download
포스터
Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/Glucagon triple agonist in the neurodegenerative disease models
American diabetes association (ADA) 78th Scientific sessions, 2018
Download
포스터
Effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in a NASH and fibrosis animal model
American diabetes association (ADA) 78th Scientific sessions, 2018
Download
포스터
Bone protective effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in an animal model
American diabetes association (ADA) 78th Scientific sessions, 2018
Download
발표
Novel combination of a long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) and once-weekly basal insulin (HM12460A) offers improved glucose lowering and weight loss in a diabetic animal model
American diabetes association (ADA) 78th Scientific sessions, 2018
Download
포스터
Neuroprotective effects of HM15211, a novel long-acting GLP-1/Glucagon/GIP tri-agonist in the MPTP Parkinson's disease mouse model
European association for the study of diabetes (EASD) 53rd Annual meeting, 2017
Download
발표
Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211)
European association for the study of diabetes (EASD) 53rd Annual meeting, 2017
Download
포스터
Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP triple-agonist (HM15211)
American diabetes association (ADA) 77th Scientific sessions, 2017
Download
포스터
Neuroprotective effects of HM15211, a novel long-acting GLP-1/Glucagon/GIP triple agonist in the MPTP Parkinson's disease mouse model
American diabetes association (ADA) 77th Scientific sessions, 2017
Download